BCL2L1 and pancreatic neoplasm: In short, the combined treatment of the CDK5 inhibitor analogue 24 and the BCL-XL inhibitor navitoclax synergistically stimulated apoptosis and suppressed cancer cell growth in pancreatic cancer cell lines compared to single-drug therapy [76].